| Literature DB >> 25773151 |
Egil Røsjø1, Kjell-Morten Myhr2, Kristin I Løken-Amsrud3, Søren J Bakke4, Antonie G Beiske5, Kristian S Bjerve6, Harald Hovdal7, Finn Lilleås8, Rune Midgard9, Tom Pedersen10, Jūratė Šaltytė Benth11, Øivind Torkildsen12, Stig Wergeland13, Annika E Michelsen14, Pål Aukrust15, Thor Ueland14, Trygve Holmøy16.
Abstract
To explore if vitamin D modulates interferon-β1a treatment effects in relapsing-remitting multiple sclerosis, we examined relationships between serum vitamin D and magnetic resonance imaging (MRI) activity and ten systemic inflammation markers in 88 patients, before and during treatment. Odds ratios for all MRI parameters were negatively associated with vitamin D levels before therapy, but converged to equally low values irrespective of vitamin D status during treatment. During therapy, similar alterations of MRI activity and inflammation markers were found across patients categorized by mean vitamin D values. This suggests that vitamin D status has no major influence on interferon-β1a treatment effects.Entities:
Keywords: Interferon-β treatment; Relapsing-remitting multiple sclerosis; Vitamin D
Mesh:
Substances:
Year: 2015 PMID: 25773151 DOI: 10.1016/j.jneuroim.2015.02.001
Source DB: PubMed Journal: J Neuroimmunol ISSN: 0165-5728 Impact factor: 3.478